Argo Blockchain
ARBK
Strategy
MSTR
BTCS Inc
BTCS
Canaan
CAN
Bit Origin
BTOG
US Stock MarketDetailed Quotes
NKTR Nektar Therapeutics
- 0.9826
- +0.0908+10.18%
Close Feb 14 16:00 ET
- 1.0000
- +0.0174+1.77%
Post 20:01 ET
181.25MMarket Cap-1.17P/E (TTM)
1.0800High0.9005Low6.89MVolume0.9300Open0.8918Pre Close6.84MTurnover4.15%Turnover RatioLossP/E (Static)184.46MShares1.928052wk High3.71P/B162.94MFloat Cap0.650052wk Low--Dividend TTM165.83MShs Float111.3600Historical High--Div YieldTTM20.13%Amplitude0.4126Historical Low0.9930Avg Price1Lot Size
Trending Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Nektar Therapeutics Stock Forum
$Nektar Therapeutics (NKTR.US)$
taking a position here
The FDA's Fast Track designation for rezpegaldesleukin marks a important inflection point for Nektar Therapeutics in the $14 billion global atopic dermatitis market. The designation's significance extends beyond mere regulatory acceleration - it validates the drug's novel approach in a highly competitive landscape dominated by JAK inhibitors and biologics like Dupixent.
The drug's mechanism of action targeting regulatory T c...
Nektar's Breakthrough: FDA Accelerates Path for Revolutionary Skin Disease Treatment
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
Monday, 10th February at 7:00 am
SAN FRANCISCO, Feb. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older with moderate-to-sever...
The completion of target enrollment in REZOLVE-AD Phase 2b trial represents a significant milestone for Nektar's rezpegaldesleukin program. The 396-patient study achieved enrollment in just 14 months, indicating strong interest from both physicians and patients. The trial's design is particularly robust with its multi-regional approach spanning Europe (67%), US (17%), Canada (11%) and Australia (5%).
The study's focus on treatment-naïve p...
Nektar Therapeutics Announces Completion of Target Enrollment in Rezolve-Ad Phase 2B Clinical Trial of Rezpegaldesleukin in Patients With Moderate-to-Severe Atopic Dermatitis
For Nektar Therapeutics, with its modest market cap of $193.7M, these results could be transformative. The CAR-T therapy market is projected to grow significantly and NKTR-255's potential to enhance existing CAR-T treatments positions it well for partnerships or licensing deals. The data showing superior complete response rates compared to historical benchmarks could translate to significant market opportunity, especially given t...
No comment yet